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CBackground: Approximately 80% of cervical cancer cases occur in de-
veloping countries. In Thailand, cervical cancer has been the leading
cancer in females, with an incidence of 24.7 cases per 100,000 individ-
uals per year.Objectives: Weconstructed a decisionmodel to simulate
the lifetime economic impact for women in the context of human pap-
illomavirus (HPV) infection prevention. HPV-related diseases were of
interest: cervical cancer, cervical intraepithelial neoplasia, and genital
warts. The two strategies used were 1) current practice and 2) prophy-
lactic quadrivalent vaccine against HPV types 6, 11, 16, and 18.
Methods: We developed a Markov simulation model to evaluate the
incremental cost-effectiveness ratio of prophylactic HPV vaccine.
Women transition through a model either healthy or developing HPV
or its related diseases, or die from cervical cancer or from other causes
according to transitional probabilities under the Thai health-care con- O
T
a
w
e
d
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al So
oi:10.1016/j.jval.2011.11.007ext. Costs from a provider perspective were obtained from King Chu-
alongkorn Memorial Hospital. Costs and benefits were discounted at
% annually. Results: Compared with no prophylactic HPV vaccine, the
ncremental cost-effectiveness ratio was 160,649.50 baht per quality-ad-
usted life-year. Themortality ratewas reducedby54.8%.The incidenceof
ervical cancer, cervical intraepithelial neoplasia grade 1, cervical intra-
pithelial neoplasia grade 2/3, and genital warts was reduced by up to
5.1%. Conclusion: Compared with commonly accepted standard
hresholds recommended by theWorldHealthOrganizationCommission
n Macroeconomics and Health, the nationwide coverage of HPV vacci-
ation in girls is likely to be cost-effective in Thailand.
eywords: cost-effectiveness, developing countries, HPV vaccine.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cervical cancer is the second most common female malignancy
worldwide. Approximately 80% of all cases occur in developing
countries and predominantly in low socioeconomic populations
[1–4]. Results from many studies suggest that infection with hu-
man papillomavirus (HPV) is the first step in the development of
cervical cancer [5–7]. There are more than 100 types of papilloma
iruses (HPVs) that infect humans. Types 16 and 18 were the most
ommon types identified in patients with cervical cancer inWest-
rn countries (70%–85% of cases) [8–13].
In Thailand, cervical cancer has been the leading cancer in
emales, accounting for 24.7 new cases per 100,000 individuals per
ear [14,15]. Furthermore, cervical cancer has been identified as a
ational public-health problem [16,17]. Among a population of
2.2 million women in 2008, there were an estimated 8000 new
ases and about 2178 deaths [18,19]. HPV types 16 and 18 account
or 52% and 19% of cervical cancers, respectively [20]. HPV type 16
as detected in 48% and type 18 in 16% of individualswith cervical
ntraepithelial neoplasia (CIN) grade 3 [21].
On the basis of this evidence, great effort has been undertaken
o develop effective HPV vaccines [22]. Currently, HPV vaccines
ave been approved worldwide for preventing cervical cancer and
ther HPV-related diseases [23]. Several mathematical models
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to evaluate the cost-effectiveness of the HPV vaccine [12,24–33].
his study used a different approach. We modeled a treatment
lgorithm reflecting standard practice for individuals with genital
arts, CIN1, CIN2/3, as well as cervical cancer and compared the
ffect that vaccine would have on the population of patients who
id and did not receive prophylactic HPV vaccination.
Objectives
We therefore aimed to perform a cost-effectiveness evaluation of a
prophylactic HPV (6, 11, 16, 18) vaccination program compared with
current management from a care provider perspective under the
Thaihealth-caremanagement settingas thenominatedcomparator.
Methods
Simulation model
Wedeveloped amutually exclusive state-transitionMarkovmodel
[34,35] to clearly depict the clinical management algorithm of
treatments for genital warts, CIN, and various stages of cervical
cancer (Fig. 1) as defined by the Federation of Gynaecology and
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Williamstown, MA). Our hypothetical longitudinal entire lifetime
cohort was 12-year-old girls who never had sexual intercourse.
The cohort was followed through different health states until age
100 years. In yearly cycles, each girl had her own outcome and
moved through health states. Women could transition healthy or
develop HPV and its related diseases as a result of diagnosis, or
they could die from cervical cancer or other causes according to
transitional probabilities. In an attempt to decrease bias and im-
prove the quality of the data used to calculate the transition prob-
abilities required by themodel, the authors reviewed the literature
thoroughly and systematically for data on Thai health outcomes.
When adequate Thai data were not available, we used data from
the Asia-Pacific or other regions and experts’ opinion.
The age-specific incidence of cervical cancer was obtained
from the National Cancer Institute, Ministry of Public Health
(MoPH), Thailand. The number of noncervical cancer deaths was
estimated by using Thai female lifetable statistics [36]. Data are
shown in Table 1.
Assumptions
The main assumptions of the model were as follows:
1. Vaccination was at the age of 12 years.
2. The proportion of women taking immunization was 100% and
varied in the sensitivity analysis.
. The duration of vaccine protectionwas lifelong, with a vaccina-
tion cost of 6189 Thai baht per three-dose course.
. The efficacy of the quadrivalent vaccine against HPV types 6, 11,
16, and 18, based on literature review, was estimated at 97%
[53]. In the sensitivity analyses, alternative assumptions were
investigated by varying this efficacy from 90% to 99.9% and
cross-protection between types was not taken into account.
. Because theMarkovModel did not have the ability to remember
prior events, we assumed that women who were treated and
were cured returned to the healthy state and had a probability
of redeveloping a disease similar to those of women without
prior disease.
. The Federation of Gynaecology and Obstetrics stages classifica-
tion and treatment algorithm would not change over time.
Cost of care
To assess the costs of care, we conducted the analysis from the
Fig. 1 – Simple schematic model to portray the algorithm of
treatments of genital warts, cervical intraepithelial
neoplasia (CIN), and stages for cervical cancer. CIN, cervical
intraepithelial neoplasia; IA1, cervical cancer stage IA1;
IA2–IIA, cervical cancer stage IA2–IIA; IIB–IVA, cervical
cancer stage IIB–IVA; IVB, cervical cancer stage IVB.perspective of a health-care provider. Costs, expressed in ThaiTable 1 – Baseline values in the model.
Variable Base case Reference
Annual probability of death
(from all causes)
[36]
10–14* 0.001
50–54 0.0134
95–99 0.8103
Annual incidence of cervical
cancer
24.7 per 100,000 [37]
15–19* 1 per 100,000
50–54 74 per 100,000
70–74 61 per 100,000
Annual incidence of CIN1 120 per 100,000 [38]
15–19* 160 per 100,000
20–24 510 per 100,000
70 20 per 100,000
Annual incidence of CIN2/3 80 per 100,000 [38]
15–19* 90 per 100,000
25–29 380 per 100,000
70 1 per 100,000
Annual incidence of genital
warts
231 per 100,000 [39]
10–14* 10 per 100,000
20–24 861 per 100,000
45 48 per 100,000
5-y cancer survival (%)
Stage IA1 94.3 [40]
Survival of recurrence 93.7 [41]
Stage IA2, IB, IIA 88.8 [42]
Survival of recurrence 83.3 [41]
Stage IIB–IVA 67.6 [43]
Survival of recurrence 53.0 [43]
Stage IVB 22 [44]
5-y progression-free survival (%)
Stage IA1 92 Assumed
Stage IA2, IB, IIA 80 [45]
Stage IIB–IVA 6 Assumed
Median progression-free
survival: Stage IVB (mo)
3.8 [46]
Annual recurrence rate:
CIN1 (%)
9 [47]
Annual recurrence rate: CIN2/
3 (%)
11.9 [48]
Annual recurrence rate:
genital warts (%)
39 [49]
Prevalence of HPV16 or 18 in
CIN (%)
75 [21]
Prevalence of HPV16 or 18 in
cervical cancer (%)
85.5 [50]
Prevalence of HPV6 or 11 in
genital warts (%)
80 [51]
Quality of life of patients with Mean (SD) [52]
Genital warts 0.743 (0.12)
CIN1 0.787 (0.09)
CIN2/3 0.776 (0.13)
IA1 0.784 (0.13)
IA2, IB, IIA 0.788 (0.13)
IIB–IVA 0.776 (0.13)
IVB 0.814 (0.12)
CIN, cervical intraepithelial neoplasia; IA1, cervical cancer stage
IA1; IA2, cervical cancer stage IA2; IB, cervical cancer stage IB; IIA,
cervical cancer stage IIA; IIB–IVA, cervical cancer stage IIB–IVA; IVB,
cervical cancer stage IVB.
* Calculate in 5-y age categories; only lowest, middle, and highest
a3
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were provided by the Center of Health Assurance at King Chula-
longkorn Memorial Hospital (Table 3). The medical costs associ-
ated with each procedure were separated into major categories:
cost of treatment of genital wart and cost of treatment of cervical
cancer (composed of medical treatment and surgical treatment as
well as costs for chemotherapy and radiotherapy administration,
and cost of palliative treatment for those patients who need sup-
portive care). Capital cost and labor cost were already included in
the unit cost for inpatient and outpatient services.
Costs in baht were converted to US dollar by using the ex-
change rate of 35 bahts per dollar.
Benefit
The qualitative measure of health utilities ranged from a mini-
mum of 0 (death) to a maximum of 1 (perfect health). For long-
term cost utility analysis, we used quality of patient’s life (Table 1)
obtained from our previous study [52] and enumerated in quality-
djusted life-years.
Future costs and benefit were discounted at an annual rate of
.0% [54]. The results of cost-effectiveness analysis were summa-
ized by the use of incremental cost-effectiveness ratios (ICERs).
Sensitivity analysis
We conducted sensitivity analyses via Monte Carlo simulation to
evaluate the robustness of our conclusions over a range of impor-
tant parameters. Beta distribution was used to calculate any prob-
abilities, and Gamma distribution was applied to unit costs in
probabilistic sensitivity analysis.
Because of the skewness in cost distribution, the ranges of
costs were varied 10% below and three times above the base-case
estimation.
The cost of the vaccine was also varied to include the range of
values that have been used in a previous study [55].
For clinical variables, the range of variations likely to be en-
countered in the clinical setting was based on discussions with
experts. In one sensitivity analysis, 10,000model simulationswere
Fig. 2 – Model validity. Comparison of model-predicted and
observed data for age-specific incidence of cervical cancer.
Solid line represents the model prediction of cervical
cancer in Thailand. Circle represents Thailand incidence
data obtained from the National Cancer Institute, Ministry
of Public Health [56].completed.Model validity
To validate themodel, we compared the incidence of cervical can-
cer cases and deaths predicted by our Markov model with those
reported by the National Cancer Institute and the MoPH (Fig. 2).
Our model had a shape and a peak that were similar to those
reported. The incidence rate according to the model was 24.3 per
100,000, which is slightly less than but very close to the incidence
rate given by the MoPH (24.7 per 100,000).
The model gave a cervical cancer mortality rate of 7.99 per
100,000. The crude death rate given by the MoPH was 5.2 per
100,000 for the year 2007.
Results
Base-case-analysis and sensitivity analysis
Under the base-case scenario, a prophylactic HPV vaccine for 12-
year-old girls was more expensive than current practice but also
resulted in greater quality-adjusted life-year (Table 2). The ICER
was 160,649.50 bahts per quality-adjusted life-year.
HPV vaccine reduces the lifetime number of cervical cancer
cases and deaths by 55%. Furthermore, cases of CIN1, CIN2/3, and
genital warts were reduced by 51% to 54% (Table 2). One-way sen-
sitivity analysis was performed around the range of unit costs,
vaccine price, discount rate, quality of life, and parameters as out-
lined in Table 3. Changes in clinical variables altered the amount
of ICER but did not alter the conclusions. Not surprisingly, the
cost-effectiveness ratio was sensitive to changes in vaccine price
and percentage of girls covered by the vaccination program. The
model showed that the ICER was beyond the usual accepted
Table 2 – Difference between vaccinated and
unvaccinated cohort of 100,000 women at base-case
parameters.
Vaccinated Unvaccinated
Total costs of cohort
(baht)
803,464,334.7 398,873,486.4
SD*  78,059,309.5 SD*  173,033,801.8
Incremental cost (baht) 404,590,848.3
Total QALY of cohort 2,659,620.8 2,657,102.3
SD*  6,678.4 SD*  15,341.6
Incremental QALY 2,518.5
ICER (baht/QALY) 160,649.5
Health outcomes
Cervical cancer
incidence
10.9/100,000 24.3/100,000
Reduction (%) 55.1
Cervical cancer
mortality
3.25/100,000 7.19/100,000
Reduction (%) 54.8
Genital wart annual
incidence
196.4/100.000 406.18/100.000
Reduction (%) 51.6
CIN1 annual
incidence
63.5/100.000 138.85/100.000
Reduction (%) 54.3
CIN 2/3 annual
incidence
30.89/100.000 67.08/100.000
Reduction (%) 53.9
CIN, cervical intraepithelial neoplasia; ICER, incremental cost-ef-
fectiveness ratio; QALY, quality-adjusted life-year; SD, standard de-
viation.
* SD: standard deviation from Monte Carlo simulation.
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bled or the vaccine coverage rate was less than 80%. Change in the
utility value for genital warts had a considerable impact on the
ICER (Table 3).
Discussion
Fromthecohort of 12-year-oldgirls going through theMarkovmodel,
numerical results were compared for model simulation with and
without vaccination. In 2009, the gross national income per capita
was US$3,869 per year or 135,415 Thai bahts [57]. According to the
standard thresholds recommended by the World Health Organiza-
tion Commission on Macroeconomics and Health [58], the model
showed that HPV vaccination, comparedwith currentmanagement,
was likely to be cost-effective in Thailand. The finding of this study
agreedwith those studies conductedbyGoldie et al. [12], Sandersand
Taira [32], andTaira et al. [33]. The prophylactic quadrivalent vaccine
saved 9 quality-adjusted life-days per person (2,518.5 years per
100,000 persons). Although this is modest at the individual level, the
population benefit is comparable to vaccinations against hepatitis B
virus, pertussis, rubella, measles, or mumps, which save 3.6, 3.3, 3.0,
2.7, and 0.3 life-days, respectively [59].
Factors that most influenced the cost-effectiveness were the
ost of vaccine, the efficacy of vaccine, and the vaccine coverage
ate. Sensitivity analysis showed that the HPV vaccine would be
ost-effective even assuming the efficacy of vaccine was down
o 90%.
Concerning the cost of vaccine, the ICER would be above the
Table 3 – Results of sensitivity analysis.
Vaccine price (baht)
Unit cost for procedure (baht)
Medical treatment of warts 3348.24
Surgical treatment of warts 5,941.56
Cryotherapy 638.10
Conization 33,805.70
Total abdominal hysterectomy 39,842.29
Radical hysterectomy 101,830.80
Vaginectomy 39,156.97
Chemotherapy 270,857.28
Radiation 52,575.45
Palliative care 66,142.96
Discount rate (%)
Both costs and outcomes
Utility rate (QOL value for)
Genital warts
CIN1
CIN2/3
IA1
IA2, IB, IIA
IIB–IVA
IVB
Efficacy of vaccine (%)
Vaccine coverage (%)
Effect of human papillomavirus (HPV)
HPV 16/18 cause of cervical cancer (%)
HPV 6/11 cause of genital warts (%)
CIN, cervical intraepithelial neoplasia; IA1, cervical cancer stage IA1
cancer stage IIA; IIB–IVA, cervical cancer stage IIB–IVA; IVB, cervical c
adjusted life-year; QOL, quality of life.ecommended thresholds if the vaccine price were to double. Inthis model, we assumed lifelong immunization. To date, there are
no data to suggest that booster doses are needed but if they were,
this would increase the vaccine price and decrease its cost-effec-
tiveness [60].
High vaccine uptake rate was necessary tomaximize the effec-
tiveness of the prophylactic vaccination. Scenario analysis
showed that the more one reduces the vaccine coverage, the less
cost-effective the vaccination program was.
This study has limitations that need to be discussed further.
First, our study was conducted in a single institution. The infor-
mation on costs was obtained from King ChulalongkornMemorial
Hospital, which is a large, tertiary, government teaching hospital.
This approach would underestimate costs when compared with
private hospitals and may overestimate the costs of care in sec-
ondary or primary hospitals. To cope with this limitation, we em-
ployed Monte Carlo simulation to display the spread of expected
values when cost distributions were assigned earlier. Further-
more, in sensitivity analysis, the ranges of the costs were varied
10% below and three times above the base-case estimation.
The second limitation was the lack of country information on
age-specific incidence of genital warts and CIN. As such, we had to
adopt published data from other countries. Such an approach is
not without pitfalls as one over- or underestimates the actual dis-
ease incidence. To use the best available information, publications
were reviewed and chosen according to the experience of special-
ists on the subject.
Third, as vaccine efficacy trials have mostly used female sub-
jects [53,61], our hypothetical population were girls. Conse-
Price and cost
Range for sensitivity
analysis
ICER range
(baht/QALY)
6,189–12,378 160,649–406,394
3,013–10,045 161,990–133,881
5,347–17,825 160,887–155,900
574–1,914 160,661–160,413
30,425–101,417 163,574–102,169
35,858–119,527 161,522–143,196
91,648–305,492 161,117–151,293
35,241–117,471 160,698–159,670
243,772–812,572 161,487–143,900
47,318–157,726 161,103–151,570
59,529–189,429 161,966–136,104
2.5–6.0 152,092–295,038
0.60–0.80 51,688–1,005,734
0.60–0.80 66,313–178,281
0.60–0.80 83,608–183,737
0.60–0.80 154,044–161,251
0.60–0.80 150,602–161,337
0.60–0.80 154,815–161,479
0.60–0.85 160,069–160,748
90.0–99.9 292,115–133,352
80.0–100 394,353–160,649
70.0–90.0 259,103–145,416
70.0–90.0 221,092–127,794
, cervical cancer stage IA2; IB, cervical cancer stage IB; IIA, cervical
stage IVB; ICER, incremental cost-effectiveness ratio; QALY, quality-; IA2
ancerquently, herd immunity (i.e., the protective effect on the popula-
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[
[
[
[
[
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taken into account. However, herd immunity by vaccinatingmales
would become important if vaccine coverage of women is likely to
be less than 100% [56].
Fourth, regarding the assumption that the Markov model did
not have the ability to remember the prior events, women with
prior disease would have the same probability of redeveloping
the disease as those without prior disease. On the contrary,
from the previous clinical study [62], the probability of redevel-
oping the disease was higher in the women with prior disease.
Therefore, this would make vaccine more favorable.
Lastly, our assumption was that a vaccination program would
provide universal coverage to all 12-year-old girls rather than spe-
cific high-risk groups. Target-specific vaccination programs may
bemore cost-effective, but it is not straightforward and itmight be
untenable to reach all individuals at higher risk for HPV infection.
Conclusion
Themodel showed that the prophylactic quadrivalent vaccinewas
likely to be cost-effective in Thailand. These data are relevant for
developing countries in deciding the best allocation of their lim-
ited health-care resources.
Source of financial support: A grant for this studywas provided
byMSD (Thailand). The views expressed in this article are those of
the authors and are not endorsed by the sponsor.
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